Can we make anti-viruses(anti-virals)?

we can't fight them with antibiotic, but I have read of otherways.
By studing why enzime they use to get into the cells, we can try to create something that will block that and the virus can't get in.

Maybe this "new" technology will end up being the holy grail of the 21st century...

Steve King quotes from bio-defense speech in NYC:

www.wsw.com...

Steve King:

...."We believe we have an agent that has the potential to have some broad utility in the bio-defense area, whether it's bio-terorism or in the control of widespread viral outbreaks."

...."Tarvacin recognizes a stable target common to all enveloped viruses that cannot easily be mutated because it is derrived from the host, it's not encoded by the genome, but rather it's a stable structure of the virus particle. Examples of enveloped viruses include marburg virus, lassa fever, ebola, HIV, Hepatitis C, influenza. Secondly as I'll show you later in some preclinical data, tarvacin has shown the ability to arrest the development of disease even in late stages of infection. And thirdly- tarvacin is expected to recognize not just the known enveloped viruses that are here today, but new enveloped viruses that will undoubtedly become available and will have mutated and become new viral strains over the next years to come."

"This is an example of the enveloped viruses that are on the class-A watch list from the Center for Disease Control. You can see the viruses that are on here such as lassa fever, yellow fever, west nile virus, marburg virus...., - and the reason I put this up here is that we fully expect that tarvacin would be able to recognize all of these viral types, not just individual viruses where we'd have to develop new agents for each virus, but rather a single agent that could recognize all of these.".....

...."As a summary of the preclinical data that we've generated to date, we've found that tarvacin recognizes multiple enveloped virus strains. In fact- every enveloped virus strain we've tested to date. This data will be presented next week at Bio 2005."

Secondly, tarvacin recognizes virally infected cells from multiple virus types. This again has been shown in a number of systems and we're continuing those studies, and so far in every system we've looked at we've seen the expression of the tarvacin target on these virally infected cells.

Thirdly, tarvacin has shown activity in the treatment of animals infected with lethal doses of lassa fever which is a category-A bio-terrorism watchlist virus.

We've also seen even more significant anti-viral effects in other animal models, and again that data will be presented at the bio conference next week."

Snip.....

Here's a page which might help explain it in more readable language than the patent-

www.tarvacin.com...|ll|li|llll&mi=|l|||i||lll

Noosnomrm, if Tarvacin (the lead drug from Dr. Phil Thorpe’s Anti-Phospholipid Therapy platform) proves out in the newly initiated human trials for ALL-SOLID-CANCERS and HEPATITIS-C, it will be a major medical advancement. Remember, Tarvacin not only attacks ALL ENVELOPED VIRUSES (ex: Hep/B+C, Influenza, Pneumonia, SARS, HIV/AIDS, Ebola, Marburg, Lassa, + dozens more), but ALL SOLID TUMORS as well.

On the Anti-viral (AV) side, Tarvacin is “surprisingly effective in inhibiting the entry, replication and the spread of viral infections.” To get started understanding what it is:

How APT's work: www.peregrineinc.com...
Tarvacin (3G4) clinical trials website: Tarvacin.com...
"What is Tarvacin?": /bobex
For Cancer: /cgsv5 For Viruses: /cvfcm

Several promising aspects about TARVACIN’s potential as an ANTI-VIRAL and ANTI-CANCER treatment (ALL THESE THINGS REMAIN TO BE PROVEN IN HUMAN TRIALS):

IT APPEARS TO BE UNIVERSAL:
Bernard Wolfson in his 7-16-05 O.C.R. “High Hopes” article said, “What if someone told you they had a drug that could fight Cancer and nearly every human Virus from HIV to Hepatitis C, and from Ebola to the common flu? You might be a little surprised, a little curious, a little excited - and more than a little incredulous… The reason Tarvacin appears to have such a broad range of uses is that it targets not any specific cancer or virus, but rather a substance found in the membranes of all cells. When cells become malignant, or are infected by a virus, the substance - known as a phospholipid - moves from the inside of the membrane to the outer surface, allowing Tarvacin to bind with it. The binding marks the cell, raising a red flag that alerts the immune system to the presence of a foreign body. With viral infections, the body's white blood cells attack the viruses. With cancer, the immune system appears to destroy the blood vessels of a tumor, depriving it of the nutrients it needs to grow. ‘The concept is almost so simple it's hard to believe no one picked up on it before,’ says Steven King, Peregrine’s CEO Peregrine.” [/9e6gf ]
###This from Thorpe’s patent app #20040161429 (filed 8-15-03, pub. USPO 8-19-04), titled ‘Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipid’: [0909] “the spectrum of viral treatment for the present invention extends to any virus, whether enveloped or not, DNA or RNA. …the invention is not limited to the treatment of enveloped viruses alone, nor to any particular virus, which is an important advantage. [1302] “the 3G4 antibody has enormous potential as a broad spectrum anti-viral agent.” [ /6pdny ]
###CEO King 6-15-05, “....Examples of enveloped viruses include Marburg virus, Lassa fever, Ebola, HIV, Hepatitis C, Influenza [incl. Avian]. Secondly, as I'll show you later in some preclinical data, Tarvacin has shown the ability to arrest the development of disease even in late stages of infection. And thirdly, Tarvacin is expected to recognize not just the known enveloped viruses that are here today, but new enveloped viruses that will undoubtedly become available and will have mutated and become new viral strains over the next years to come."
[ /coomw & /e2hxh ]
###Michael Brush’s 7-28-05 “Envelope Please” article, “Most of the excitement right now surrounds potential treatments of the so-called “envelope” viruses – the ones that envelope themselves with bits the host cell membrane as they exit the host cell. The “envelope” viruses read like a top 10 list of diseases you’re most likely to get, and really don’t want. They range from Influenza and Hepatitis B and C, to Herpes, West Nile, Dengue, HIV, SARS, Avian flu and many of the potential bio-terror “hemorrhagic” viruses, like Ebola. [/9z7yf ]

IT APPEARS TO BE SAFE:
From Thorpe video 10-24-04: “Understanding Tarvacin”, incl. his first-ever public comments about Tarvacin's ANTI-VIRAL capabilities: “That's an extraordinary result, I don't know of any other antiviral agent that is known to protect against Lassa Fever. And we've also shown similar results in cytomegalovirus... at that dose we've never seen any sign of toxicity in mice or monkeys; about 14 species treated with the therapeutic dose. And that's thousands of mice & monkeys. And even if you increase the dose to 10 mg/kg, that's 10x the therapeutic dose. So the conclusions with Tarvacin are that it has a unique mechanism of action, there's nothing else like it out there.”
[/8b6kr & /dou8t ]
###From Thorpe’s APT (AntiPS/3G4/Tarvacin) patent app #20040161429 (pub. USPO 8-19-04):
[1298] “The 3G4 antibody has also been administered to monkeys in safety studies and no side effects have been observed.” [/6pdny ]
###From Thorpe’s Aug03-Jan08 $1.68mm NIH/NIAID grant for research using 3G4 as ‘Novel Anti-Viral Agents for Treating Lassa Fever’, “the phospholipids that they recognize have the same structure and cellular distribution in different mammalian species, simplifying the transition from experimental animals into humans. The antibodies arenot toxic to mice, even when administered in high doses for prolonged periods of time.” [/5ntcm ]

IT APPEARS VIRUSES CAN’T BECOME RESISTANT TO IT:
Again, from the Brush article, “A great thing about Peregrine’s approach is that viruses can’t mutate to fight off the Tarvacin attack. That’s because Tarvacin keys in on anomalies in the cell membrane – the confused phospholipids -- that viruses don’t know how to fix. ‘Since it is not made by the virus, it is not mutable by the virus,’ says Peregrine CEO Steven King. ‘It is not something the virus can change, to get away from therapy.’” [ /9z7yf ]
###From the Wolfson article, “Scientists say Tarvacin could have an advantage over other anti-viral drugs because viruses probably won't be able to evade it by mutating. ‘Mutation won't affect it because it's targeting a substance which is not intrinsic to the virus itself but to the host cell - so that substance will be there no matter what new form the virus takes,’ says Dr. Stephen M. Smith, a paid Peregrine consultant and chief of infectious diseases at the Seton Hall School of Graduate Medical Education in Orange, NJ.” [ /9e6gf ]
###CEO King 6-15-05, “Tarvacin recognizes a stable target common to all enveloped viruses that cannot easily be mutated because it is derived from the host, it's not encoded by the genome, but rather it's a stable structure of the virus particle.”
[ /coomw & /e2hxh ]

IT MAY EVEN CONFER VIRAL IMMUNITY:
From Tarvacin.com, “Tarvacin provided significant protection in animals administered lethal viral loads of pichinde virus (a model of Lassa fever) with 50% of the Tarvacin treated animals surviving and none of the animals receiving control treatment surviving. Moreover, Tarvacin treated guinea pigs who survived the infection became immune to subsequent infections with the same viral strain. An interesting hypothesis still to be tested is whether treatment of one virus with APT agents confers protection against infection by other enveloped viruses. [/cvfcm ]
###From BIO2005, “Animals lethally infected with Pichinde virus that survived following Tarvacin therapy had long term immunity to reinfection.” [/dqf9t]

= = = = = = =
To learn more about Thorpe & Tarvacin:

/b9hdq - my amateur compilation of Articles, Quotes, Patents, History, etc.
. . .Make sure you hit the “Thorpe's Patents & Pub's” button and read APT Patent #20040161429 (pub. by USPO 8-19-04), “Compositions for treating Viral Infections using Immunoconjugates to Aminophospholipids”.

[edit on 15-8-2005 by cjgaddy]